A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

ABSTRACT: WT2725 is a Wilms' tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1⁺ tumors in human leukocyte antigen (HLA)-A*0201⁺ and/or HLA-A*0206⁺ patients. Here, we report the results of a phase I study of WT2725. In this phase I, open-label, dose-escalation and expansion two-part study, the WT2725 dosing emulsion was administered as a monotherapy to patients with advanced malignancies known to overexpress WT1, including glioblastoma. In part 1, 44 patients were sequentially allocated to four doses: 0.3 mg (n = 5), 0.9 mg (n = 5), 3 mg (n = 6), and 9 mg (n = 28). In part 2, 18 patients were allocated to two doses: 18 mg (n = 9) and 27 mg (n = 9). No dose-limiting toxicities were observed, so the maxim

SUBMITTER: Fu S 

PROVIDER: S-EPMC8595891 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature